PacBio has announced its participation in the 1000 Genomes Long Read Sequencing Project, contributing long-read transcriptome data to enhance this significant human genomics initiative. Through ...

Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely available to scientists worldwide The Importance of Long-Read Sequencing for ...

Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.

MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PacBio (PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a significant advancement for global ...

Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.

MENLO PARK, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced its entry into the ...

Pacific Biosciences of California is back in focus after analysts cut their price target to $1.50 from $2, while a separate fair value estimate was trimmed to $2.43 from $2.50. This shift is tied to ...

The National Institute on Aging’s Long Life Family Study (LLFS) selected PacBio technology to generate genomic and epigenomic data from as many as 7,800 participants. The effort will rely on PacBio’s ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, recently announced that its HiFi whole-genome sequencing technology has been adopted as a first-line approach in a major ...

Pacific Biosciences of California Inc. (NASDAQ:PACB) on Wednesday announced preliminary revenue of $36.9 million versus a consensus of $33.49 million. The company said the first quarter met ...

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its peers.